Every 8-K that Elite Pharmaceuticals Inc (ELTP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ELTP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELTP filings page.
Elite Pharmaceuticals, Inc. reported financial results for the first quarter of fiscal year 2027, ended June 30, 2026. Consolidated revenues were $32.4 million, a decrease of $7.9 million or about 19.5% from the same quarter of the prior fiscal year, which had been its largest quarterly revenue. Income from operations was $7.5 million, down $14.2 million or about 65%, primarily due to lower margins on sales of the company’s generic Vyvanse product line as competitive market adjustments weighed more heavily on this quarter.
The company stated that, despite the year-over-year decline, first-quarter results are in line with the three preceding quarters. Net income attributable to common shareholders was $5.9 million. Management will discuss the results and provide a business update on a conference call scheduled for August 14, 2026 at 11:30 AM EDT.
Elite Pharmaceuticals, Inc. filed an amended current report to correct the previously stated conference-call deadlines from November to August. The company plans to release financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, on August 13, 2026. Management will then host a conference call on August 14, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update. Investors can join via domestic dial-in 1-800-346-7359 or international 1-973-528-0008 using conference number 98840, and are invited to submit general and financial questions by specified email deadlines prior to the call. An audio replay will be available online.
Elite Pharmaceuticals, Inc. reported that it will release financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, on August 13, 2026. Management will then host a live conference call on August 14, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update.
Investors can join the call via domestic dial-in 1-800-346-7359 or international dial-in 1-973-528-0008, using conference number 98840. Stockholders are invited to submit general and financial questions in advance to dianne@elitepharma.com by the deadlines provided in the notice.
Elite Pharmaceuticals, Inc. reported the commercial launch of its generic version of Requip XL (Ropinirole Extended-Release Tablets USP) in the United States. The product is offered in 2 mg, 4 mg, 6 mg, 8 mg and 12 mg strengths and is marketed and sold under the Elite Laboratories, Inc. label.
Ropinirole is a non-ergoline dopamine agonist used to treat Parkinson’s disease. According to IQVIA, the branded product and its equivalents generated $10 million in total U.S. sales for the twelve months ending June 2026, providing an indication of the market size for this therapy class.
Elite Pharmaceuticals reported sharply improved results for the fiscal year ended March 31, 2026. Consolidated revenues reached $148.9 million, an increase of $64.8 million, or about 77%, over the prior year. Income from operations was $49.1 million, up $29.5 million, or roughly 151%.
The company attributed the stronger operating income mainly to a full-year contribution from its Lisdexamfetamine product, revenues from Oxycodone Acetaminophen tablets launched during the year, and Naltrexone and Phentermine tablets sold exclusively under the Elite label, along with broad growth across its product lines.
Management will discuss these year-end 2026 results and recent business developments on a conference call scheduled for June 30, 2026 at 11:30 AM EDT, with domestic and international dial-in numbers and an audio replay link provided.
Elite Pharmaceuticals, Inc. filed an 8-K to announce timing for its fiscal year 2026 results and a related conference call. The company will release financial results for the year ended March 31, 2026 on June 29, 2026.
Management will host a live conference call on June 30, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update. Investors can join using domestic dial-in 1-800-346-7359 or international 1-973-528-0008 with conference number 98840, and are invited to email questions in advance.
Elite Pharmaceuticals reported positive results from a pivotal bioequivalence study for an undisclosed generic anticonvulsant. The study showed the generic is bioequivalent to the branded drug, meaning it delivers the same amount of active ingredient into the bloodstream under the test conditions.
The trial used an open-label, randomized, two-period crossover design in healthy adults under fasting conditions, which is a standard approach for bioequivalence work. Elite is now compiling the data to file an Abbreviated New Drug Application with the US Food and Drug Administration, the key regulatory step needed to market the product in the United States.
IQVIA reported combined branded and generic product sales for this market of $840 million for the twelve months ending April 2026, highlighting the commercial scale of the opportunity if Elite’s generic ultimately secures approval and market access.
Elite Pharmaceuticals, Inc. filed a Current Report to highlight that it has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for a generic drug in the anticoagulant class. The branded reference product generated $26 billion in sales for the twelve months ending March 2026, according to IQVIA, and currently has no generic competition.
The brand still has unexpired patents and regulatory exclusivities listed in the FDA’s Orange Book, so any future generic launch would depend on FDA approval and successfully addressing these protections. The press release with additional details is furnished as an exhibit and is treated as furnished, not filed, under securities laws.
Elite Pharmaceuticals, Inc. has commercially launched its generic methadone hydrochloride 5 mg and 10 mg tablets in the United States under the Elite Laboratories, Inc. label. These tablets are used for severe, persistent pain and for detoxification and maintenance treatment of opioid addiction alongside medical and social support services.
Based on IQVIA data, combined brand and generic methadone tablet products generated approximately $22 million in annual retail sales in 2025, indicating a modest but established market. Elite develops and distributes niche generic, oral controlled-release drugs from its cGMP and DEA-registered facility in Northvale, New Jersey.
Elite Pharmaceuticals, Inc. reported very strong results for the third quarter of fiscal 2026, the three months ended December 31, 2025. Consolidated revenues were $31.6 million, up $17.2 million or about 120% from the same period a year earlier. Income from operations reached $9.0 million, an increase of $7.9 million, roughly 721% higher than the prior-year quarter, driven mainly by sales of Elite’s lisdexamfetamine and naltrexone products and strong growth in Elite label products. Net income for the quarter was $18.6 million. Management will discuss these results and recent business developments on a conference call scheduled for February 18, 2026, at 11:30 EST.
Elite Pharmaceuticals, Inc. filed a current report announcing it will release financial results for the third quarter of fiscal year 2026, ended December 31, 2025, on February 17, 2026. Management will host a conference call on February 18, 2026 at 11:30 EST to discuss the results and provide a corporate update.
Investors can join the call by dialing 1-800-346-7359 (domestic) or 1-973-528-0008 (international) using conference number 98840, and are invited to email general and financial questions in advance to dianne@elitepharma.com by the specified deadlines.
Elite Pharmaceuticals (ELTP) filed an 8-K noting it filed its Form 10‑Q for the quarter ended September 30, 2025 and issued a press release with those results. The company will host a conference call on November 17, 2025 at 11:30 AM EST to provide a business update and answer pre-submitted stockholder questions.
Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international), conference number 98840. Financial questions may be emailed to dianne@elitepharma.com by 7:00 PM EST on November 14, 2025. An audio replay will be available at https://elite.irpass.com/events_presentations.
Elite Pharmaceuticals (ELTP) filed an 8-K/A to amend its earlier report, solely to correct the date of its conference call. The company will host the call to discuss financial results for the second quarter of fiscal 2026, covering the period ended September 30, 2025.
The conference call is scheduled for Monday, November 17, 2025, at 11:30 AM EST. Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (international), conference number 98840. General questions may be emailed to dianne@elitepharma.com by 5:00 PM EST on November 13, 2025, and financial questions by 7:00 PM EST on November 14, 2025. The information is being furnished under Items 2.02, 7.01 and 9.01 and is not deemed filed under the Exchange Act.
Elite Pharmaceuticals (ELTP) announced FDA approval for its generic version of Requip XL (Ropinirole Extended-Release Tablets USP). The approval covers 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths used to treat symptoms of Parkinson’s disease. The product will be marketed and sold under the Elite Laboratories, Inc. label.
The company furnished a press release with these details as Exhibit 99.1. Information in this item and the press release is provided under Regulation FD and is not deemed filed under the Exchange Act.
Elite Pharmaceuticals (ELTP) announced it will host a conference call to discuss its second quarter fiscal 2026 results for the period ended September 30, 2025. The call is scheduled for November 14, 2025, at 11:30 AM EST.
Participants can dial 1-800-346-7359 (domestic) or 1-973-528-0008 (international) and use conference number 98840. Questions may be emailed to dianne@elitepharma.com; general questions are due by 5:00 PM EST on November 13, 2025, and financial questions by 7:00 PM EST on November 14, 2025.